Skip to main content
OpenTrials
Completed

NCT Number: NCT05141903

Dietary Supplement With and Without a Probiotic and/or Antibiotic

Complex oligosaccharides can alter the gut microbiome by aiding in the growth of certain organisms, and possibly, inhibiting others. The synergy with a probiotic may enhance gastrointestinal colonization.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Altasciences

Cypress, California, 90630, United States

About this study

The study will evaluate the synergy of the use of a complex oligosaccharide with and without a probiotic on the human microbiome in healthy volunteers who have received antibiotics. The combination should support general gastrointestinal health.

This study is a multi-dose randomized cohort trial using 18 subjects per cohort for a total of 90 healthy adult volunteers ages 18-75.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy adults between the ages of 18-75 years (subjects must be 18-75 at the time of consent) who can provide proof of vaccination against SARS-CoV-2. Proof may be a physical or electronic record of vaccination or self-attestation (to include approximate vaccination date and manufacturer of vaccine) if a copy of the vaccination record is not available
  • Subjects must have a BMI of 18 - 30 at screening visit
  • Willingness to complete study specific questionnaires
  • Willingness to complete journal to record IP dosing times, Bristol stool scores, and IP flavor questionnaires
  • Willingness to complete all study procedures, clinic visits, and provide required biospecimen samples
  • Willingness to collect and process stool samples at home and transport stool samples to clinic
  • Sexually active females of child-bearing potential must agree to use highly effective methods of contraception during heterosexual intercourse throughout the study period and for three days following discontinuation of IP, whichever comes later. Examples of highly effective methods include the use of two forms of contraception with one being an effective barrier method (e.g., a condom and spermicide used together), or have a vasectomised partner. Abstinence is acceptable as a life-style choice. Female subjects who utilize hormonal contraceptives as one of their birth control methods must have used the same method for at least 3 months before study dosing
  • Provide informed consent

Exclusion criteria

  • Subjects with a BMI of 17 or less or 31 or greater are excluded
  • Women who are pregnant or breastfeeding, or intend to become pregnant during the course of this study
  • Subjects who intend to take a probiotic during the study
  • Subjects with self-reported diarrhea on day 1 prior to dosing, whereby diarrhea is defined as two or more episodes of watery and/or unformed stool within 24 hours
  • Alcohol or drug abuse during the last 12 months, including passing a screen for drugs of abuse at screening and day 1 of the study
  • Unstable medical condition, in the opinion of the investigator
  • Subject with a history of allergy to the study antibiotics
  • Clinically significant abnormal laboratory test results at screening
  • Subjects who are unable or unwilling to provide stool samples on a regular basis as per study protocol
  • Participation in a clinical research trial within 30 days prior to screening
  • Unable to give informed consent
  • Any condition which may preclude subject's ability to comply with and complete the study or may pose a risk to the health of the subject
  • Known carriers of C. difficile prior to study start, as determined by qPCR of stool
  • Known carriers of vancomycin-resistant enterococci (VRE) prior to study start, as determined by stool culture
  • Subjects with history of lactose intolerance

Treatment and study plan

Antibiotic

Dietary Supplement

Vancomycin (250 mg/dose), Metronidazole (500 mg/dose)

HMO Concentrate

Dietary Supplement

Concentrated milk fortifiers from donor human milk

Probiotic

Dietary Supplement

B. infantis

Food supplement

Dietary Supplement

Synthetic powder containing 2'-fucosyllactose (2'-FL) and lactoneotetraose (LNnT)

Primary outcomes

  1. Evaluation of the Changes in Microbiome Species Abundance and Diversity From Baseline Until End of Study (Day 35)

    Time frame: Baseline, Day, 5, 14, 35

    Evaluation of HMO supporting gut colonization of B.infantis in healthy adult volunteers with microbiome disruption by antibiotics. Stool samples were taken from subjects at regular intervals and prepared for DNA extraction and microbiome analysis. Following DNA extraction, samples were analyzed using subspecies-specific qPCR analysis to evaluate B.infantis colonization and monitor overall shifts using primers that target universal 16S rRNA gene shared by bacteria by log-fold changes.

Secondary outcomes

  1. Changes in Immune Markers Assessment at Day 5, 14 and 28

    Time frame: Baseline-28 days

    Blood samples were collected at regular intervals for serum immunological parameters (LAP-TGFB, MCP1, MIP-1) to assess metabolite levels.

  2. Blood Pressures of Subjects From Baseline to Day 35

    Time frame: Day 0 - 35

    Clinical assessments from baseline throughout study to assess vital signs of subject safety (blood pressure [BP]). Descriptive statistics performed by dose group and visit.

  3. Heart Rates of Subjects From Baseline to Day 35

    Time frame: Day 0-35

    Clinical assessment from baseline throughout study to assess vital signs of subject safety (heart rate). Descriptive statistics performed by dose group and visit.

  4. Respiratory Rates of Subjects From Baseline to Day 35

    Time frame: Day 0-35

    Clinical assessment from baseline throughout study to assess vital signs of subject safety (respiratory rate). Descriptive statistics performed by dose group and visit.

  5. Temperatures of Subjects From Baseline to Day 35

    Time frame: Day 0-35

    Clinical assessment from baseline throughout study to assess vital signs of subject safety (temperature).

Sponsors and collaborators

Lead sponsor

Prolacta Bioscience

Industry

Registry information

Official study title

Dietary Study of a Complex Oligosaccharide With and Without a Probiotic Following Antibiotic Treatment in Healthy Volunteers

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Dec 2, 2021
Registry last updated
Feb 17, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.